CSL Seqirus awarded BARDA flu vaccine contract

CSL Seqirus is set to complete the fill and finish process for pre-pandemic vaccine to support the US government’s outbreak and preparedness response.

CSL Seqirus, a subsidiary of Australia’s CSL Limited (ASX: CSL), has been selected by the USA’s Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), to complete the fill and finish process of pre-pandemic vaccine for the US government as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program.

CSL Seqirus global executive director Marc Lacey noted that the CDC maintains the risk to public health as low, and the company is closely monitoring the situation because it is acutely aware of the threat that influenza virus strains like H5N1 can pose.